| MCS+AT1R (n=76) | ||||
|---|---|---|---|---|
| Endpoints | Binding Level | Binding Level>40 U/ml (n=52) | MCS w/o AT1R (n=92) | P-Value |
| Incidence of PGD, % | 0.0% (0/24) | 7.8% (4/52) | 6.5% (6/92) | 0.396 |
| 1 Year Survival | 90.5% | 90.2% | 92.8% | 0.780 |
| 1 Year Freedom from CAV | 89.7% | 93.8% | 94.1% | 0.858 |
| 1-Freedom from NF-MACE | 87.0% | 91.9% | 84.0% | 0.432 |
| 1-Freedom from Any-Treated Rejection | 94.4% | 85.5% | 81.4% | 0.344 |
| 1 Year Freedom from Acute Cellular Rejection | 100.0% | 98.0% | 95.2% | 0.492 |
| 1 Year Freedom from Antibody-Mediated Rejection | 100.0% | 91.5% | 94.3% | 0.387 |